Rossari Biotech Future Growth
Future criteria checks 4/6
Rossari Biotech is forecast to grow earnings and revenue by 22.3% and 16.6% per annum respectively. EPS is expected to grow by 22.3% per annum. Return on equity is forecast to be 15.4% in 3 years.
Key information
22.3%
Earnings growth rate
22.3%
EPS growth rate
Chemicals earnings growth | 23.0% |
Revenue growth rate | 16.6% |
Future return on equity | 15.4% |
Analyst coverage | Low |
Last updated | 23 Oct 2024 |
Recent future growth updates
Recent updates
Why We Think Rossari Biotech Limited's (NSE:ROSSARI) CEO Compensation Is Not Excessive At All
Aug 17Is Rossari Biotech (NSE:ROSSARI) Using Too Much Debt?
Jun 14Rossari Biotech's (NSE:ROSSARI) Solid Profits Have Weak Fundamentals
May 07Analyst Estimates: Here's What Brokers Think Of Rossari Biotech Limited (NSE:ROSSARI) After Its Annual Report
May 03One Analyst Just Shaved Their Rossari Biotech Limited (NSE:ROSSARI) Forecasts Dramatically
Feb 10Returns On Capital At Rossari Biotech (NSE:ROSSARI) Paint A Concerning Picture
Sep 23Returns On Capital Signal Tricky Times Ahead For Rossari Biotech (NSE:ROSSARI)
Apr 06Need To Know: Analysts Are Much More Bullish On Rossari Biotech Limited (NSE:ROSSARI) Revenues
Feb 19Rossari Biotech Limited Just Beat Revenue Estimates By 6.8%
Feb 17I Ran A Stock Scan For Earnings Growth And Rossari Biotech (NSE:ROSSARI) Passed With Ease
Feb 10Capital Allocation Trends At Rossari Biotech (NSE:ROSSARI) Aren't Ideal
Nov 24With EPS Growth And More, Rossari Biotech (NSE:ROSSARI) Is Interesting
Oct 12Is Rossari Biotech Limited's (NSE:ROSSARI) Latest Stock Performance Being Led By Its Strong Fundamentals?
Dec 17Rossari Biotech (NSE:ROSSARI) Is Growing Earnings But Are They A Good Guide?
Oct 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 28,895 | 2,388 | 1,624 | 2,222 | 3 |
3/31/2026 | 24,403 | 1,871 | 1,080 | 2,015 | 4 |
3/31/2025 | 20,636 | 1,496 | 586 | 2,355 | 4 |
9/30/2024 | 19,245 | 1,388 | 17 | 1,162 | N/A |
6/30/2024 | 19,096 | 1,364 | N/A | N/A | N/A |
3/31/2024 | 18,306 | 1,307 | -880 | 433 | N/A |
12/31/2023 | 17,643 | 1,255 | N/A | N/A | N/A |
9/30/2023 | 16,898 | 1,168 | -341 | 631 | N/A |
6/30/2023 | 16,318 | 1,078 | N/A | N/A | N/A |
3/31/2023 | 16,559 | 1,073 | 1,187 | 1,516 | N/A |
12/31/2022 | 16,883 | 1,027 | N/A | N/A | N/A |
9/30/2022 | 17,275 | 995 | 729 | 990 | N/A |
6/30/2022 | 16,866 | 1,018 | N/A | N/A | N/A |
3/31/2022 | 14,830 | 977 | -89 | 294 | N/A |
12/31/2021 | 12,623 | 957 | N/A | N/A | N/A |
9/30/2021 | 10,438 | 948 | -342 | 129 | N/A |
6/30/2021 | 8,310 | 892 | N/A | N/A | N/A |
3/31/2021 | 7,093 | 802 | -103 | 478 | N/A |
12/31/2020 | 6,507 | 729 | N/A | N/A | N/A |
9/30/2020 | 6,031 | 695 | 198 | 1,045 | N/A |
6/30/2020 | 5,818 | 666 | N/A | N/A | N/A |
3/31/2020 | 6,001 | 653 | -191 | 568 | N/A |
3/31/2019 | 5,162 | 457 | 272 | 712 | N/A |
3/31/2018 | 2,922 | 254 | N/A | 254 | N/A |
3/31/2017 | 2,350 | 143 | N/A | 67 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROSSARI's forecast earnings growth (22.3% per year) is above the savings rate (6.7%).
Earnings vs Market: ROSSARI's earnings (22.3% per year) are forecast to grow faster than the Indian market (18.1% per year).
High Growth Earnings: ROSSARI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ROSSARI's revenue (16.6% per year) is forecast to grow faster than the Indian market (10.5% per year).
High Growth Revenue: ROSSARI's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROSSARI's Return on Equity is forecast to be low in 3 years time (15.4%).
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 22:11 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Rossari Biotech Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
null null | Anand Rathi Shares and Stock Brokers Limited |
Bhawana Israni | Anand Rathi Shares and Stock Brokers Limited |
Rohit Nagraj | Centrum Broking Limited |